ホーム>>Signaling Pathways>> Immunology/Inflammation>> Autoimmunity>>MOG (35-55) (mouse, rat) (trifluoroacetate salt)

MOG (35-55) (mouse, rat) (trifluoroacetate salt) (Synonyms: MEVGWYRSPFSRVVHLYRNGK, Myelin Oligodendrocyte Glycoprotein (35-55))

カタログ番号GC52419

MOG抗原ペプチド

Products are for research use only. Not for human use. We do not sell to patients.

MOG (35-55) (mouse, rat) (trifluoroacetate salt) 化学構造

サイズ 価格 在庫数 個数
500 μg
$101.00
在庫あり
1 mg
$192.00
在庫あり
5 mg
$601.00
在庫あり
10 mg
$1,001.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Myelin oligodendrocyte glycoprotein (MOG) (35-55) is an antigen peptide of MOG, a protein involved in demyelinating CNS disorders.1,2 MOG (35-55) in combination with heat-killed M. tuberculosis and complete Freund's adjuvant (CFA) induces demyelination of the spinal cord, degeneration of the optic nerve, and visual impairments in mice.1 Immunization with MOG (35-55) in combination with adjuvants has been used to induce experimental autoimmune encephalomyelitis (EAE) in animal models of multiple sclerosis.1,2

1.Guo, X., Harada, C., Namekata, K., et al.Delayed onset of experimental autoimmune encephalomyelitis in Olig1 deficient micePLoS One5(9)e13083(2010) 2.Zhang, F., Wei, W., Chai, H., et al.Aurintricarboxylic acid ameliorates experimental autoimmune encephalomyelitis by blocking chemokine-mediated pathogenic cell migration and infiltrationJ. Immunol.190(3)1017-1025(2013)

レビュー

Review for MOG (35-55) (mouse, rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MOG (35-55) (mouse, rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.